...
首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >A randomized, open-label, single-visit crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD
【24h】

A randomized, open-label, single-visit crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD

机译:一项随机,开放标签,单次访问的交叉研究,模拟COPD患者使用Ellipta与双吸入器组合进行三药递送

获取原文
           

摘要

Background: Administering maintenance COPD therapy with a combination of multiple inhalers may increase inhaler errors. This study evaluated the potential benefits of using a single Ellipta dry powder inhaler (DPI) compared with two combinations of DPIs commonly used to deliver triple maintenance therapy. Methods: Patients receiving inhaled COPD medication were enrolled in this multicenter, randomized, open-label, placebo-device, crossover study with a 2×2 complete block design (NCT0298218), which comprised two substudies: Ellipta vs Diskus + HandiHaler?(substudy 1) or Turbuhaler + HandiHaler (substudy 2). Patients demonstrated inhaler use after reading the relevant patient information leaflet (PIL). A trained investigator assessed user errors (critical errors [errors likely to result in no or significantly reduced medication being inhaled] and overall errors). The primary endpoint was the proportion of patients making?≥1 critical error after reading the PIL. The secondary endpoints included error rates during?≤2 reassessments following investigator instruction (if required), instruction time, and patient preference. Results: After reading the PIL, significantly fewer patients made critical errors with Ellipta compared with Diskus?+?HandiHaler (9% [7/80] vs 75% [60/80], respectively; P 0.001) or Turbuhaler?+?HandiHaler (9% [7/79] vs 73% [58/79], respectively; P 0.001). The number of patients making overall errors was also lower with Ellipta vs tested inhaler combinations ( P 0.001 for each substudy). The median instruction time needed for error-free use was shorter with Ellipta in substudies 1 and 2 (2.7 and 2.6 minutes, respectively) vs either combination (10.6 [Diskus + HandiHaler] and 11.3 minutes [Turbuhaler + HandiHaler], respectively). Significantly more patients preferred Ellipta over Diskus?+?HandiHaler or Turbuhaler?+?HandiHaler overall for taking their COPD medication (81% vs 9% and 84% vs 4%, respectively) and per the number of steps for taking their COPD medication (89% vs 8% and 91% vs 5%, respectively). Conclusion: Fewer patients with COPD made critical errors with the single DPI, and patients required less instruction time, compared with each dual DPI combination.
机译:背景:联合使用多个吸入器进行维持性COPD治疗可能会增加吸入器错误。这项研究评估了使用单一Ellipta干粉吸入器(DPI)与通常用于提供三重维持治疗的两种DPI组合的潜在益处。方法:接受吸入COPD药物治疗的患者参加了这项多中心,随机,开放标签,安慰剂装置,具有2×2完整模块设计(NCT0298218)的交叉研究,该研究包括两个子研究:Ellipta vs Diskus + HandiHaler? 1)或Turbuhaler + HandiHaler(子研究2)。阅读相关患者信息单(PIL)后,患者证明已使用吸入器。训练有素的研究人员评估了使用者的错误(严重错误[错误,这些错误可能导致没有吸入或大大减少药物的吸入]和整体错误。主要终点是读取PIL后发生≥1个严重错误的患者比例。次要终点包括根据研究者的指导(如果需要)在≤2的重新评估期间的错误率,指导时间和患者喜好。结果:读取PIL后,与Diskus?+ HandiHaler相比,发生Ellipta严重错误的患者明显少得多(分别为9%[7/80]和75%[60/80]; P <0.001)或Turbuhaler?+? HandiHaler(分别为9%[7/79]和73%[58/79]; P <0.001)。与试验的吸入器组合相比,使用Ellipta产生总体错误的患者数量也更低(每个子研究P <0.001)。与子组合(分别为10.6 [Diskus + HandiHaler]和11.3分钟[Turbuhaler + HandiHaler])相比,在Ellipta的子研究1和2中,无错误使用所需的中位指令时间更短(分别为2.7和2.6分钟)。总体而言,在服用COPD药物方面(按比例分别为81%对9%和84%对4%)和按服用COPD药物的步骤数来看,更多的患者偏爱Ellipta而不是Diskus®?HandiHaler或Turbuhaler?+?HandiHaler。 89%vs 8%和91%vs 5%)。结论:与每种双重DPI组合相比,较少的COPD患者使用单一DPI发生严重错误,并且患者需要更少的指导时间。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号